Author

Husain Yar Khan

Wayne State UniversityORCID 0000-0002-9161-1514Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Amro AboukameeliD· 3 shared Bassel F. El‐RayesiD· 3 shared Boris PascheiD· 3 shared Herbert R. CheniD· 3 shared Hugo JimeneziD· 3 shared Md. Hafiz UddiniD· 3 shared Rafic BeydouniD· 3 shared Ramzi M. MohammadiD· 3 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Amro AboukameelORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways

Md. Hafiz Uddin, Zaid K Mahdi, Irfana Muqbil, Brendon Herring, Rose J. Bart, Husain Yar Khan, Yiwei Li, Amro Aboukameel, Sahar F. Bannoura, Hugo Jimenez, Allan M. Johansen, Mohammad Najeeb Al-Hallak, Ibrahim Hanna Azar, Amr Mohamed, Tarik H. Hadid, , Asfar S. Azmi

This study identifies key oncogenic pathways and targetable genes in MEN1-wild-type low-grade pancreatic NETs that drive metastasis, offering a therapeutic strategy based on pathway intensity rather than mutation count.

International Journal of Biological Sciences · Sep 3, 2026Peer-reviewedCancer Biology

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer

Sahar F. Bannoura, Husain Yar Khan, Amro Aboukameel, Yin Wan, Bin Bao, Md. Hafiz Uddin, Hugo Jimenez, Adeeb Aboukameel, Rayyan Siddiqui, Filza Khan, Pouya Haratipour, Long Gu, Rafic Beydoun, M. W. Saif, Miguel E. Tobon, , Asfar S. Azmi

This study shows that combining PCNA inhibitor AOH1996 with KRAS inhibitors enhances antitumor activity in pancreatic cancer models.

bioRxiv · Dec 10, 2025 · PreprintCancer Biology

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma

Husain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, Sahar F. Bannoura, Md. Hafiz Uddin, Adeeb A. Aboukameel, Fulya Koksalar Alkan, Ahmet B. Çağlayan, Hilmi Kaan Alkan, Bin Bao, Hugo Jimenez, Allan M. Johansen, Callum T. McGrath, Grayson Barker, Khalil Choucair, , Asfar Sohail Azmi

This paper shows that combining Eltanexor and MRTX1133 improves efficacy in KRASG12D mutant PDAC by overcoming resistance and reducing tumor growth.

bioRxiv · Nov 21, 2025 · PreprintCancer Biology